Skip to main content

2 Result(s)

within Vrutti Patel Remove this filter

and

  1. Article

    Open Access

    Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

    Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleu...

    Guido Ghilardi, Luca Paruzzo, Vrutti Patel… in Journal of Hematology & Oncology (2024)

    Download PDF (1604 KB) View Article

  2. No Access

    Article

    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon ...

    Guido Ghilardi, Joseph A. Fraietta, James N. Gerson… in Nature Medicine (2024)